Research
Hormonal
Gut microbiota-derived metabolites, specifically Short-Chain Fatty Acids (SCFAs) like butyrate, acetate, and propionate, ameliorate NAFLD by inhibiting histone deacetylases (HDACs) and activating G-protein coupled receptors (GPR41, GPR43).
Eating soluble dietary fibers feeds gut bacteria to produce Short-Chain Fatty Acids (SCFAs) like butyrate. These metabolites help reduce liver inflammation and fat accumulation by regulating gene expression and immune responses. Focus on fiber-rich foods rather than isolated SCFA supplements.
ModerateSupportsMEDIUM confidence
SCFAs regulate the metabolism and immune functions of liver tissue mainly through the inhibition of histone deacetylases or the activation of G-protein coupling receptors including GPR41, GPR43, GPR109a, and OLFR78.
Why this rating
Based on animal models and mechanistic reviews; clinical translation is suggested but not fully elucidated.
Source
Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD)
Yun Ji et al. · Nutrients · 2019
DOI 10.3390/nu11081712
narrative_reviewCited 225×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Gut microbiota-derived lipopolysaccharides (LPS) and peptidoglycan (PGN) promote NAFLD progression by activating hepatic Toll-like receptors (TLR4, TLR2, NOD1/2), triggering inflammatory cytokine release and steatosis.Moderate
- Gut microbiota-derived Trimethylamine-N-oxide (TMAO) and secondary bile acids modulate NAFLD progression through regulation of bile acid metabolism, insulin resistance, and hepatic inflammation.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →